These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Search MEDLINE/PubMed
Title: Identification of natural compounds with anti-hepatitis B virus activity from Rheum palmatum L. ethanol extract. Author: Li Z, Li LJ, Sun Y, Li J. Journal: Chemotherapy; 2007; 53(5):320-6. PubMed ID: 17785969. Abstract: BACKGROUND: Hepatitis B virus (HBV) infection is a severe health problem in the world; however, there is still no satisfactory therapeutic strategy for the HBV infection. In search for new anti-HBV agents with higher efficiency and less side effects, the anti-HBV activities of traditional Chinese medicine Rheum palmatum L. ethanol extract (RPE) and isolated anthraquinones were evaluated. METHODS: The anti-HBV activities of RPE and isolated anthraquinones were demonstrated in a stable HBV-producing cell line HepG2 2.2.15 by using real-time polymerase chain reaction (PCR), enzyme-linked immunosorbent assay (ELISA) and Southern blot analysis. RESULTS: RPE could inhibit HBV-DNA production and HBsAg expression in a dose-dependent manner. The concentration of 50% HBV-DNA inhibition (IC(50)) of RPE was calculated at 212.36 +/- 11 microg/ml. Six anthraquinones were isolated from RPE by using RP-HPLC. Five free anthraquinones showed weakly or slightly inhibitory activities against HBV. The only combined anthraquinone chrysophanol 8-O-beta-D-glucoside exhibited significant activity against HBV DNA production and antigens expression with an IC(50) value of 36.98 +/- 2.28 microg/ml on HBV DNA inhibition. Endogenous HBV DNA polymerase activity assay indicated that chrysophanol 8-O-beta-D-glucoside might be a potential inhibitor of the HBV DNA polymerase. CONCLUSIONS: The results suggested that RPE could effectively inhibit HBV. The combined anthraquinone chrysophanol 8-O-beta-D-glucoside is the major active compound in RPE and could be a promising candidate for the development of new anti-HBV drugs in the treatment of HBV infection.[Abstract] [Full Text] [Related] [New Search]